References
- LiowKBarkleyGLPollardJRHardenCLBazilCWAmerican Academy of NeurologyPosition statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology20076816 1249 125017438213
- PeruccaEAlbaniFCapovillaGBernardinaBDMichelucciRZaccaraGRecommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugsEpilepsia200647Suppl 5 16 2017239100
- American Epilepsy SocietyAES position on the substitution of different formulations of antiepileptic drugs for the treatment of epilepsy2007 Available from: https://www.aesnet.org/sites/default/files/file_attach/AboutAES/PositionStatements/position%20statement%20on%20substitution%20of%20generic%20formulations.pdfAccessed March 1, 2017
- National Institute for Health and Care Excellence (NICE)Epilepsies: diagnosis and treatment. Clinical guideline [CG137]2012 [updated 2016]. Available from: http://www.nice.org.uk/guidance/cg137Accessed January 20, 2017
- PriviteraMDWeltyTEGidalBEGeneric-to-generic lamotrigine switches in people with epilepsy: the randomized controlled EQUIGEN trialLancet Neurol2016154 365 37226875743
- VosslerDGAndersonGDBainbridgeJAES position statement on generic substitution of antiepileptic drugsEpilepsy Curr2016163 209 21127330454
- AndermannFDuhMSGosselinAParadisPECompulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classesEpilepsia2007483 464 46917346246
- RascatiKLRichardsKMJohnsrudMTMannTAEffects of anti-epileptic drug substitutions on epileptic events requiring acute carePharmacotherapy2009297 769 77419558250
- ZachryWM3rdDoanQDClewellJDSmithBJCase-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changesEpilepsia2009503 493 50018616554
- GagneJJAvornJShrankWHSchneeweissSRefilling and switching of antiepileptic drugs and seizure-related eventsClin Pharmacol Ther2010883 347 35320631693
- LabinerDMParadisPEManjunathRGeneric antiepileptic drugs and associated medical resource utilization in the United StatesNeurology20107420 1566 157420393142
- HartungDMMiddletonLSvobodaLMcGregorJCGeneric substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover studyCNS Drugs2012268 707 71622731934
- ChaluvadiSChiangSTranLGoldsmithCEFriedmanDEClinical experience with generic levetiracetam in people with epilepsyEpilepsia2011524 810 81521426334
- VariMSPintoFMencaroniESafety of overnight switch from brand-name to generic levetiracetamClin Drug Investig2016361 87 91
- SchefferIEBerkovicSCapovillaGILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminologyEpilepsia2017584 512 52128276062
- KesselheimASStedmanMRBubrickEJSeizure outcomes following the use of generic vs brand-name antiepileptic drugs: a systematic review and meta-analysisDrugs2010705 605 62120329806
- DuhMSParadisPELatrémouille-ViauDThe risks and costs of multiple-generic substitution of topiramateNeurology20107224 2122 2129
- RediguieriCFZeredoJLAssessing bioequivalence of antiepileptic drugs: are the current requirements too permissive?J Pharm Pharm Sci2014172 220 22824934550
- TingTYJiangWLionbergerRGeneric lamotrigine vs brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standardEpilepsia2015569 1415 142426201987
- LessingCAshtonTDavisPThe impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New ZealandAppl Health Econ Health Policy2014125 537 54625005492
- KesselheimASBykovKGagneJJWangSVChoudhryNKSwitching generic antiepileptic drug manufacturer not linked to seizures: a case-crossover studyNeurology20168717 1796 180127683844
- DavitBMNwakamaPEBuehlerGJComparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug AdministrationAnn Pharmacother20094310 1583 159719776300